Hello, everyone, and welcome to the middle of the week. Time flies when you are … quarantined? Well, so much in life is a matter of perception, yes? Nonetheless, you have made it this far, so time to celebrate with a delicious cup of stimulation. Our choice today is vanilla caramel cream. One can never be too sweet, after all. Please feel free to join us. Meanwhile, here is the latest menu of tidbits to get you going. Hope your day is productive and safe. And as always, please do keep in touch. …

Heavy hearts soared with news the Moderna (MRNA) Covid-19 vaccine candidate — the frontrunner in the U.S. market — seemed to generate an immune response in Phase 1 trial subjects. Its market cap surged to $29 billion, an astonishing feat for a company that currently sells zero products. But was there good reason for so much enthusiasm? Several vaccine experts told STAT that, based on the information made available by the company, there is really no way to know how impressive — or not — the vaccine may be.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy